Parameswaran Venugopal to Radiopharmaceuticals
This is a "connection" page, showing publications Parameswaran Venugopal has written about Radiopharmaceuticals.
Connection Strength
0.024
-
Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):467-74.
Score: 0.024